More than 82 million people could be living with dementia by 2030,1 the majority in low-income and middle-income countries ...

Rates of diagnosis and treatment are low, so there is a need for diagnostic tests and biomarkers for classification and ...

This research offers hope. By finding brain diseases earlier, we might be able to slow them down or manage them better. If ...

One-third of people older than 85 in the United States are estimated to live with Alzheimer's disease today, according to the ...

Cambridge-based Biogen is looking to the growth of its Alzheimer’s drug Leqembi to offset the decline of its multiple ...

New drugs show promise, and research finds value in vaccines, antivirals, exercise and probiotics.

In a major new finding almost a decade in the making, researchers at Harvard Medical School say they’ve found a key that may ...

Blood biomarkers might signal Alzheimer’s risk long before symptoms emerge, offering a possible tool for early prevention. A ...

NIH funding for research on Alzheimer’s and other forms of dementia has risen from $562 million in 2014 to $3.9 billion in 2024.

Community and research will remain priorities for the Alzheimer’s Association over the next 10 years, Maria Carrillo, PhD, and Joanne Pike, DrPH, said during a question-and-answer session at the ...